Stock Tip Tuesday

$PALI: Low Float, High Heat, and a $14 PT?

Stock Tip Tuesday…

Nasdaq: $PALI ( ▼ 1.02% ) : Low Float, High Heat, and a $14 PT?

Happy Leonardo Dicaprio GIF by Jordan Belfort

Disseminated on Behalf of Palisade Bio Inc.

Shamless Shill
This Stock Has The Potential to Fix Your Shit

Today we’re talking about Palisade Bio $PALI ( ▼ 1.02% ) -  a Nasdaq-listed microcap that's swinging for the fences in the bowel disease game - micro float under 5M shares, machine learning-powered trials, and a $14 analyst target

No, I am not shitting you and neither is this stock!

Anal-aysis
PALI’s Setup: Small Float. Big Pipe Dream.

You opened this email today to get shilled - so here you go: 

  1. $14 Analyst Target.
    That’s 1600% upside. According to the research universe of Ladenburg Thalmann Co. Inc., they believe $PALI has the potential to reach $14.

  2. 4.46M Float.
    You know the drill, all the best things in life come tight. If we see successful human trials and this thing catches some attention, we could be in for some serious fun.

  3. Massive TAM (total addressable market)
    The inflammatory Bowel Disease (IBD) market is projected to hit $31B by 2034.

  4. Drug Is in Human Trials NOW.
    Topline data dropping end of May. One good PR and… you’ve seen these tight float biotechs in action - I don't have to tell you what could happen…

Anal-aysis
So, What Do They Actually Do?

Confused Pulp Fiction GIF

Palisade’s lead asset PALI-2108, is a gut-restricted PDE4 inhibitor. That means it delivers its anti-inflammatory effect right where it’s needed, the colon, without blasting your whole body and frying your CNS.

Translation: Kills the colitis, and skips the side effects.

They’re also using machine learning to identify ideal patients for their trials, filtering out the fluff and zeroing in on responders like a sniper with AI.

Biotech x Silicon Valley - In the colon.

Anal-aysis
If You like TA, This Chart Setup Could be a Cooker

Lastly, if you geek out to a good TA setup, $PALI ( ▼ 1.02% ) just broke above its 5-day EMA, 13-day EMA, 20-day SMA, and 50-day SMA.

Thank you
That’s All Folks

Closing notes: This is a high-risk, potentially high-reward, low-float biotech heater entering a $31B+ market with machine learning-enhanced trials and a $14 price target.

If the May data drop hits? This thing could teleport.

But right now, it’s got everything we like:

  • Science

  • Machine learning

  • 1600% PT

  • Micro float 

Disclaimer

This content is not financial advice, and nothing in this communication should be interpreted as a recommendation, solicitation, or offer to buy or sell any securities. VHLA Media is not registered with the U.S. Securities and Exchange Commission (SEC), the British Columbia Securities Commission (BCSC), or any other securities regulatory authority in any jurisdiction. We are not licensed financial professionals, and do not provide personalized investment advice of any kind.
VHLA Media Inc. has been engaged by a third party, TD Media LLC, to provide marketing and advertising services on behalf of Palisade Bio Inc. We have received total compensation of USD $6,000 for our services, which include, but are not limited to, the production and distribution of this newsletter, social media marketing, and related promotional content.VHLA Media does not currently own any shares of Palisade Bio Inc., but may buy or sell shares in the open market at any time without prior notice. The content provided reflects our own subjective opinions and is intended strictly for informational and marketing purposes only.
Investing in securities, especially those traded on public markets such as NASDAQ, carries inherent risks. Readers should assume that all information in this communication is purely promotional. Any forward-looking statements are speculative in nature, involve known and unknown risks and uncertainties, and actual results may differ materially from those expressed or implied.
Before making any investment decision, you should conduct your own independent due diligence and consult with a licensed investment advisor, registered broker-dealer, or other qualified financial professional. Do not rely on our content as the basis for any financial decision. By consuming this content, you acknowledge and agree to the terms of this disclaimer.
Palisade Bio Inc. is a publicly traded company on the NASDAQ. All investors are strongly urged to review the company’s filings with the U.S. Securities and Exchange Commission (SEC), and, if applicable, disclosures made to the British Columbia Securities Commission (BCSC) or other relevant regulators.
You are solely responsible for your own investment decisions. We accept no liability for any loss or damage arising from reliance on our content.
For our full legal disclaimer and terms of use, please visit: www.vhlamedia.com/terms-disclaimer